Vor Biopharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VOR research report →
Range $27 – $31
Price Chart
About the company
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials.
- CEO
- Jean-Paul Kress
- IPO
- 2021
- Employees
- 76
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on VOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.25B
- P/E
- -0.07
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -6.26
- EV/EBITDA
- 1.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -91.63%
- ROIC
- -32.21%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-371,642,000
- Net Income
- $-695,981,000-495.3%
- EPS
- $-70.50-107.4%
- OCF Growth
- -43.2%
- FCF Growth
- -43.8%
- 52W High
- $50.20
- 52W Low
- $6.50
- 50D MA
- $18.98
- 200D MA
- $15.20
- Beta
- 1.72
- RSI (14)
- 61
- Avg Volume
- 1.17M
No earnings-call transcripts are available for VOR yet.
- Free Float
- 520.4%
- Shares Outstanding
- 54.19M
- Float Shares
- 281.98M
of shares held by institutions
62 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 770.25K | ▲ 665.06K |
Held by 122 ETFs
Biggest fund positions in VOR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 2,100,000 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 2,100,000 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 213 |
| Jul 7, 26 | ZACCARDELLI DAVID | other | 0 |
| Jul 7, 26 | ZACCARDELLI DAVID | other | 42,658 |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 57,162 |
| Jun 11, 26 | Detheux Michel | other | 57,162 |
| Jun 11, 26 | Namouni Fouad | other | 56,549 |
| Jun 11, 26 | Joustra Wouter | other | 57,162 |
| Jun 11, 26 | Kalir Erez | other | 57,162 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VOR coverage
Recent articles, reports, and earnings notes.
No research on VOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VOR report →Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 11
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 3
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 3
Vor Bio Appoints David Zaccardelli to Board of Directors
globenewswire.com · Jul 7
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
seekingalpha.com · Jul 7
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 2
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 2
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
globenewswire.com · Jun 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.